Abstract |
Cetirizine is a potent, selective H1 antagonist recently made available for investigation. To evaluate this oral drug's efficacy in treating asthma, we examined the bronchodilator effects of 5-, 10-, and 20-mg doses as well as the protective effects of these doses against histamine-provoked bronchospasm. Cetirizine's efficacy was compared with that of a placebo and oral hydroxyzine (25 mg) in 10 patients with mild asthma. The new compound provided significant protection in a dose-dependent manner against histamine-induced bronchospasm. A 25-mg oral dose of hydroxyzine, which is partially metabolized to cetirizine, yielded blood levels of cetirizine comparable to those attained with 5 mg of oral cetirizine. Hydroxyzine 25 mg conferred greater protection against histamine bronchoprovocation than placebo, but it gave less protection than 10- and 20-mg doses of cetirizine. Cetirizine in all doses, as well as hydroxyzine at 25 mg, produced significant bronchodilation. However, the bronchodilator effect of the 25-mg hydroxyzine dose was less than that of cetirizine at 20 mg. In this short-term study, no significant side effects of cetirizine were noted.
|
Authors | D P Tashkin, A Brik, H Gong Jr |
Journal | Annals of allergy
(Ann Allergy)
Vol. 59
Issue 6 Pt 2
Pg. 49-52
(Dec 1987)
ISSN: 0003-4738 [Print] United States |
PMID | 2892450
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Bronchodilator Agents
- Histamine H1 Antagonists
- Hydroxyzine
- Histamine
- Cetirizine
|
Topics |
- Adult
- Analysis of Variance
- Asthma
(drug therapy)
- Bronchial Provocation Tests
- Bronchial Spasm
(chemically induced, prevention & control)
- Bronchodilator Agents
- Cetirizine
- Dose-Response Relationship, Drug
- Female
- Histamine
(administration & dosage)
- Histamine H1 Antagonists
(adverse effects, pharmacology, therapeutic use)
- Humans
- Hydroxyzine
(adverse effects, analogs & derivatives, pharmacology, therapeutic use)
- Male
|